How might brain volume loss impact #MultipleSclerosis patients? During #MSVirtual2020, learn more about the relationship between MS and the brain.
— Bristol Myers Squibb (@bmsnews) September 11, 2020
#MEDIA: Learn how we’re accelerating progress across cancers with high unmet needs through our upcoming presentations at this year’s #ESMO20 congress. https://t.co/FMk23QXxgz pic.twitter.com/Gur4aqi9hz
— Bristol Myers Squibb (@bmsnews) September 8, 2020
Genetic abnormalities can silence genes that usually suppress tumors in the body, which can lead to the development of different cancers. Research around gene modifying therapies may play a role in identifying new potential #cancer treatments.
— Bristol Myers Squibb (@bmsnews) September 3, 2020
In acute myeloid #leukemia, if patients achieve remission, their odds of long-term survival are typically low, fueling our research for new options that may extend patients' overall survival.
— Bristol Myers Squibb (@bmsnews) September 2, 2020
Every 3 minutes, someone in the U.S. is diagnosed with a #bloodcancer. During #BloodCancerAwarenessMonth, we’ll be shining a spotlight each week on our advocacy partners who support people with a form of the disease. #BMSBloodCancerRelay
— Bristol Myers Squibb (@bmsnews) September 1, 2020
Answer: Low blood pressure is not a risk factor for #NASH. Learn more about NASH during #ILC2020: https://t.co/6llwmBCAMk pic.twitter.com/OBpJubhSSJ
— Bristol Myers Squibb (@bmsnews) August 28, 2020
Our Chief Medical Officer, Global Drug Development, Samit Hirawat shares how BMS helped patients overcome barriers to clinical trial participation and advanced its pipeline amid the global pandemic.
— Bristol Myers Squibb (@bmsnews) August 27, 2020
CEO Giovanni Caforio, PhRMA chair, recognizes We Work for Health Champions and all members of the industry’s workforce for their round-the-clock work during #COVID19. https://t.co/Ok7iTteA9w
— Bristol Myers Squibb (@bmsnews) August 27, 2020
With Bristol Myers Squibb Foundation support, 200+ volunteers with @montclairstateu Shield Our Heroes produced over 30k face shields for health facilities in New Jersey during #COVID19.
— Bristol Myers Squibb (@bmsnews) August 18, 2020
#DYK a #mesothelioma prognosis varies based on what type of cell is involved? See how research aims to uncover new possibilities for all patients with malignant pleural #mesothelioma.
— Bristol Myers Squibb (@bmsnews) August 8, 2020
Announcing our Q2 2020 results, including revenues of $10.1 billion, GAAP loss per share of $0.04 and non-GAAP earnings per share of $1.63. Read our press release here: https://t.co/HfCyqsbpuP pic.twitter.com/KxquLld1Bv
— Bristol Myers Squibb (@bmsnews) August 6, 2020
#MEDIA: #EMA validates application for our #celltherapy for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma and follicular lymphoma grade 3B https://t.co/6YuWdKEk0r pic.twitter.com/9sbjRJg53Q
— Bristol Myers Squibb (@bmsnews) July 17, 2020
CEO Giovanni Caforio, PhRMA chair, sees great progress for cancer patients and important medical advances while viewing inevitable setbacks as an opportunity to learn more in the fight against cancer. https://t.co/dfQwQeWuCv
— Bristol Myers Squibb (@bmsnews) July 16, 2020
Our Occupational Health Lead David Shepperly oversees the well-being of 30k colleagues worldwide, part of a team coordinating our #COVID19 efforts to protect our workforce to ensure we can continue to deliver medicines to our patients. https://t.co/hjteUuHLkb via @BW
— Bristol Myers Squibb (@bmsnews) July 15, 2020
Will the pharmaceutical industry keep collaborating after COVID-19? Novartis and Bristol Myers Squibb CEOs say it has to https://t.co/2d4dBMRjv5
— Bristol Myers Squibb (@bmsnews) July 8, 2020
Curious about how the #biopharma industry is adapting in the face of COVID-19? Read this article from @business on the rise of digital engagements. https://t.co/h7zE9XNW5U
— Bristol Myers Squibb (@bmsnews) June 15, 2020
Did you know that non-alcoholic steatohepatitis (#NASH) can lead to scarring of the liver called cirrhosis? On International #NASHDay, learn about this #liverdisease and see why investigating potential new treatment options is so important.
— Bristol Myers Squibb (@bmsnews) June 12, 2020
Strategic alliances are key to achieving our goal to discover, develop and deliver transformational medicines to patients. Learn more about why we partner. #BIODigital
— Bristol Myers Squibb (@bmsnews) June 10, 2020
Our CEO, Giovanni Caforio, discusses the value of collaboration and shares why he is optimistic about the future of medical research. https://t.co/RXnNMLNRBC
— Bristol Myers Squibb (@bmsnews) June 10, 2020
#DYK that #renalcellcarcinoma, the most common type of kidney cancer, is twice as common in men as it is in women?
— Bristol Myers Squibb (@bmsnews) September 17, 2020
#MEDIA: Announcing positive four-year survival data from our Phase 3 dual immunotherapy trial in previously untreated or metastatic #renalcellcarcinoma #ESMO20 https://t.co/IQkEwsJk9R pic.twitter.com/RWnyni0FX5
— Bristol Myers Squibb (@bmsnews) September 17, 2020
#AFibAwarenessMonth is the perfect opportunity to take a moment to hear what leaders from @HeartNurses want people to know about #AFib and stroke risk #AMatterofMoments
— Bristol Myers Squibb (@bmsnews) September 16, 2020
During #BloodCancerAwarenessMonth, we recognize World Lymphoma Awareness Day with a world of thanks to @LLSUsa, @knowyournodes, & @lymphoma for the important role they play in supporting people with #lymphoma #BMSBloodCancerRelay #WLAD2020
— Bristol Myers Squibb (@bmsnews) September 15, 2020
#Mesothelioma is a challenging disease with limited treatment options. By driving research advancements, we’re working to introduce potential innovations for patients.
— Bristol Myers Squibb (@bmsnews) September 15, 2020
Learn more about how #MultipleSclerosis affects patients to better understand our focus on the MS community. #MSVirtual2020
— Bristol Myers Squibb (@bmsnews) September 13, 2020
On the one-year anniversary of Business Roundtable’s Statement of Purpose of a Corporation, CEO Giovanni Caforio reflects on how to build a better, healthier world.#WorkingTogetherForPatients https://t.co/zDjPCKmIfM
— Bristol Myers Squibb (@bmsnews) September 11, 2020
We must work together to fight #healthdisparities. Read our CEO Giovanni Caforio’s message: https://t.co/HryPhTqds6 pic.twitter.com/9vA445WmeS
— Bristol Myers Squibb (@bmsnews) September 10, 2020
AFib is a type of irregular heartbeat that increases risk of stroke by up to 5x. Susan Bush from @HeartNurses highlights the importance of #AFib awareness. #AFibAwarenessMonth
— Bristol Myers Squibb (@bmsnews) September 4, 2020
#MEDIA: Announcing #FDA approval of a new therapy for people with acute myeloid #leukemia
— Bristol Myers Squibb (@bmsnews) September 1, 2020
#MEDIA: At #MSVirtual2020, interim results from our long-term Phase 3 study in patients with relapsing forms of #MultipleSclerosis will be featured, as well as data from 14 other company-sponsored and collaborative studies https://t.co/CCze5fRJjm pic.twitter.com/acIv5xSQB6
— Bristol Myers Squibb (@bmsnews) September 1, 2020
We’re glad to be part of the thriving #lifesciencesecosystem in Washington State. Hear our own Al Terry and Nathan Martin describe what it’s like to work for BMS in the Seattle area. https://t.co/cv8fvkRsVg #Biotechnology #FindYourBestLifeinWA pic.twitter.com/VO9QASPBN7
— Bristol Myers Squibb (@bmsnews) August 31, 2020
We’re looking forward to what our team will accomplish at our new combined @CXCambridge site. https://t.co/zpWAi7vD0L
— Bristol Myers Squibb (@bmsnews) August 26, 2020
Our acquisition of @Forbius_ will aid in our important work of developing new solutions for immunotherapy resistance in #cancer patients and addressing unmet medical needs. https://t.co/XahcaWRCR2 pic.twitter.com/CEpPmxCabS
— Bristol Myers Squibb (@bmsnews) August 24, 2020
Last week, we announced a $300 million commitment to accelerate #healthequity and #diversity & inclusion efforts. Join us this week as we share more on the 5 focus areas. (1/6) pic.twitter.com/BBtxpO5IAX
— Bristol Myers Squibb (@bmsnews) August 17, 2020
#MEDIA: Announcing exclusive global license with @dragonflytx for investigational #immunotherapy program. https://t.co/te2i96CRth pic.twitter.com/99okjVgzLC
— Bristol Myers Squibb (@bmsnews) August 17, 2020
“Now more than ever, we recognize our role in creating the change needed to address health disparities and racial inequality.” Our CEO Giovanni Caforio shares with the BMS community on today's announcement.
— Bristol Myers Squibb (@bmsnews) August 12, 2020
#MEDIA: Announcing positive results from our Phase 3 trial in first-line gastric and esophageal #cancers https://t.co/zec80j0dN1 pic.twitter.com/81QBAhTkFx
— Bristol Myers Squibb (@bmsnews) August 11, 2020
Hear from our Robert Plenge about the #biopharma industry’s response to #COVID19, in conversation with @ldtimmerman at @AtlanticLIVE #AtlanticPULSE.
— Bristol Myers Squibb (@bmsnews) July 31, 2020
Announcing that our Board has elected two new independent directors. Paula A. Price (l) and Derica W. Rice (r) will join the Board, effective September 1, 2020. Read our press release here: https://t.co/6tP5TMeQsg pic.twitter.com/Fkjx9SFtAk
— Bristol Myers Squibb (@bmsnews) July 30, 2020
“I give COVID as much respect as cancer.” – Donna speaks with @SterlingKBrown about what it’s like to live with #multiplemyeloma during COVID-19.
— Bristol Myers Squibb (@bmsnews) July 28, 2020
Our Chief Human Resources Officer Ann Powell takes part in a virtual panel today at the @DisabilityIN Annual Conference to discuss how we foster a culture that promotes the value of differently-abled individuals. https://t.co/PyjaXslJvv #DisabilityAdvantage pic.twitter.com/vEKSZuYgoB
— Bristol Myers Squibb (@bmsnews) July 16, 2020
Furthering our longstanding support of @SU2C, our recent grant commitment will better help identify diagnostic & treatment methods for #lungcancer patients in need.
— Bristol Myers Squibb (@bmsnews) July 16, 2020
We’re proud to partner with @LupusResearch on the first LRA-BMS Accelerator Award, supporting cutting-edge research to help advance scientific understanding and potential new treatment approaches for this complex disease.
— Bristol Myers Squibb (@bmsnews) July 15, 2020
We are pleased to help @CISCRP bridge communication and expand education in the importance of diversity in #clinicaltrials. https://t.co/hRWeHtK9pH
— Bristol Myers Squibb (@bmsnews) July 14, 2020
We are committed to reducing cancer risk for our colleagues and their families as well as patients so we’re honored to receive Global CEO Cancer Gold Standard™ accreditation in recognition of our efforts. https://t.co/LQYHakvJOH pic.twitter.com/pPJZDeqFvz
— Bristol Myers Squibb (@bmsnews) July 13, 2020
Thank you @CEOCancerfight for recognizing our commitment to the health and safety of our colleagues. https://t.co/z1kVgPLMv2
— Bristol Myers Squibb (@bmsnews) July 13, 2020
We are excited to be part of industry-wide efforts to defeat #COVID19. Learn more about the unprecedented ways biopharmaceutical companies are working together in this latest video from @PhRMA: https://t.co/ZpDG6iCdf2
— Bristol Myers Squibb (@bmsnews) June 29, 2020
#MEDIA: European Commission approves our treatment for patients with #MDS or #betathalassemia https://t.co/PtFXKoUaoJ pic.twitter.com/FMkX8394TH
— Bristol Myers Squibb (@bmsnews) June 26, 2020
Sharon Cload, our vice president of Discovery and Biotherapeutics, East Coast, looks forward to serving on the @MassBio Board of Directors to help advance Massachusetts’ leadership in the #lifesciences. https://t.co/BdZlY3vefR
— Bristol Myers Squibb (@bmsnews) June 26, 2020
Working with @GRYTHealth we’ve launched a virtual meeting place for patient advocacy organizations. Our head of Corporate Affairs, Kathryn Metcalfe, shares more. #AdvocacyExchange https://t.co/she8Jq2sY0
— Bristol Myers Squibb (@bmsnews) June 25, 2020
Ensuring all #cancer patients have access to quality care is our priority. To help improve cancer care in disadvantaged communities & direct funding to black & minority cancer researchers, we’re providing a $1m grant to @TheVFoundation Stuart Scott Memorial Cancer Research Fund. pic.twitter.com/oYaOLi9jl6
— Bristol Myers Squibb (@bmsnews) June 22, 2020
Even after #WorldBloodDonorDay, we thank blood donors for their life-saving contributions. https://t.co/3pBWlvXine
— Bristol Myers Squibb (@bmsnews) June 16, 2020
Blood cancer patients need our help now more than ever. This Blood Cancer Awareness Month, let's unite to #CancelBloodCancer. Learn more >> https://t.co/66WeCWbDaD pic.twitter.com/piYf02bKUe
— The Leukemia & Lymphoma Society (@LLSusa) September 1, 2020
https://twitter.com/CALifeSciences/status/1293939487957975042
In a huge step towards improving ED&I in the #LifeSciences, @bmsnews announced that it will commit $300 million over the next 5 years to tackle racial health disparities & accelerate its D&I efforts. Learn more: https://t.co/fhFMY2Ks6G
— MassBio (@MassBio) August 12, 2020
Diversity is long overdue in the drug industry—and it’s going to take more than just hiring Black candidates https://t.co/0ao0YWE3yJ
— FORTUNE (@FortuneMagazine) August 12, 2020
Bristol Myers Squibb commits to $300 million to combating racial inequity https://t.co/7pLrOPtgwK
— Endpoints News (@endpts) August 12, 2020
This year’s Virtual #WalkToCureArthritis was a huge success, thanks in part to our amazing, supportive #sponsors! Read more about the partners who helped us succeed during this #pandemic: https://t.co/KwH1awxXWh. #arthritis #COVID19 #coronavirus #WeLiveYes pic.twitter.com/s5ynf71MjH
— Arthritis Foundation (@ArthritisFdn) July 11, 2020
https://twitter.com/HHPHorg/status/1278386387968983046
Proud to join my @phrma colleagues in this video series that covers how the biopharmaceutical industry is working to develop safe and effective #COVID19 vaccines https://t.co/h5SpbUAzbf
— Stephen J. Ubl (@steveubl) June 29, 2020
Bristol Myers CEO Caforio on coronavirus R&D: Let's make it a 'new standard for collaboration' https://t.co/8e5kKArNSo
— FiercePharma (@FiercePharma) June 10, 2020
Lymphomas are categorized into 2 main types: Hodgkin #lymphoma or non-Hodgkin lymphoma (NHL). #DYK NHL is more common than Hodgkin lymphoma, with 7 times more case expected by 2040 #WLAD2020
— Science At BMS (@ScienceAtBMS) September 17, 2020
Myelofibrosis is a rare bone marrow cancer in which bone marrow cells that produce the blood cells develop and function abnormally. The JAK2 gene is present in more than half of these patients. #BloodCancerAwarenessMonth
— Science At BMS (@ScienceAtBMS) September 9, 2020
Learn about how deepening our understanding of the relationship between HSP47 and #fibrosis guides our research for patients with fibrotic diseases during #ILC2020.
— Science At BMS (@ScienceAtBMS) August 29, 2020
As a potential biomarker of #liverfibrosis disease activity, PRO-C3 may help us better identify and address unmet needs in #NASH. #ILC2020
— Science At BMS (@ScienceAtBMS) August 27, 2020
Gastroesophageal junction (GEJ) #cancer is an aggressive tumor that forms in the area of the digestive tract where the esophagus and stomach connect.
— Science At BMS (@ScienceAtBMS) August 12, 2020
During #ISTH2020, learn about the potential complications cancer patients can experience, including venous thromboembolism (VTE)
— Science At BMS (@ScienceAtBMS) July 10, 2020
#DYK red blood cells don’t mature properly in #MDS and targeting different stages of their maturation may lead to much-needed new treatment options for patients?
— Science At BMS (@ScienceAtBMS) June 29, 2020
Red blood cell transfusions are a cornerstone of treatment for #anemia caused by a variety of blood disorders. Frequent transfusions can burden patients, hospitals and healthcare systems.
— Science At BMS (@ScienceAtBMS) June 28, 2020
#DYK #betathalassemia can lead to the production of fewer healthy red blood cells and the development of varying degrees of #anemia?
— Science At BMS (@ScienceAtBMS) June 27, 2020
Frequent blood transfusions used to treat #MDS #anemia can be associated with an increased risk of iron overload, transfusion reactions and infections.
— Science At BMS (@ScienceAtBMS) June 26, 2020
How are researchers thinking about the next generation of CTLA-4 inhibition? Learn from our Lee James about how we’re building on today’s science to research tomorrow’s medicines. #AACR20
— Science At BMS (@ScienceAtBMS) June 21, 2020